DR30206

DRUG2 trials

Sponsors

Zhejiang Doer Biologics Co., Ltd.

Conditions

Gastrointestinal CancerSolid Tumor

Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

RecruitingNCT06132828

Zhejiang Doer Biologics Co., Ltd.Solid Tumor

Start: 2023-11-27End: 2026-07-30Target: 216Updated: 2025-07-03

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

RecruitingNCT07056777

Zhejiang Doer Biologics Co., Ltd.Gastrointestinal Cancer

Start: 2025-03-25End: 2026-06-30Target: 186Updated: 2026-01-13